22.06.2022 • News

Azelis Takes Majority Share of ROCSA Colombia

Azelis has agreed to acquire a majority stake in ROCSA Colombia, a specialty chemical distributor serving the life sciences and industrial chemical markets in South America.

Financial terms of the transaction, which is expected to close in the third quarter of 2022, were not disclosed.

Headquartered in Bogota, the company is one of Colombia’s leading specialty chemical distributors and is also present in Peru and Central America. It has over 130 employees, serving more than 1,900 customers in markets that include food & nutrition, personal care, home care & industrial cleaning, coatings, adhesives, sealants and elastomers (CASE) and plastic additives.

“Our market-leading regional expertise together with Azelis’ strong global network brings us a powerful international reach, which will benefit our diverse range of principals and customers,” said ROCSA’s CEO, Carlos Yaipen. “We look forward to leveraging Azelis’ leadership in sustainability, digitalization and innovation, and we’re confident that ROCSA will thrive under Azelis’ ownership.”

Azelis said the addition of ROCSA’s portfolio of products and capabilities is a significant milestone in its strategy in South America. Earlier this month, the multinational distribution group opened a new headquarters in Mexico City, the latest in a series of major developments in Mexico over the past few years to grow its operations in Latin America.

Author: Elaine Burridge, Freelance Journalist

© azelis
© azelis

Company

Logo:

Azelis Corporate Services NV

12 box 6, Posthofbrug
2600 Antwerpen
Belgium

Company contact







Interview

The UK Chemical Supply Chain
Trade and Competitiveness

The UK Chemical Supply Chain

The CBA, led by CEO Tim Doggett, is steering the UK chemical supply chain through trade uncertainty, sustainability pressures and logistics challenges, as he explains in this interview with CHEManager.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read